CAG预激方案联合左旋门冬酰胺酶和泼尼松诱导治疗复发难治性前体淋巴细胞白血病／淋巴瘤

Treatment of relapsed/refractory precursor lymphocytic leukemia/lymphoma by combination of CAGregimen with L-asparaginase and prednisone

目的寻找复发难治性前体淋巴细胞白血病／淋巴瘤诱导缓解的有效方法。方法以CAG预激方案联合左旋门冬酰胺酶（L-Asp）和泼尼松（PDN）诱导治疗6例复发难治性前体淋巴细胞白血病／淋巴瘤和1例急性杂合细胞白血病。结果6例患者完全缓解（CR），1例部分缓解（PR），总有效率100％（7／7），cR率85．7％（6／7）。患者不良反应轻，均可耐受。结论CAG联合L-Asp和PDN是复发难治性前体淋巴细胞白血病／淋巴瘤值得尝试的诱导化疗方案。

Objective To explore the effective treatment with regimen of remission induction for relapsed/refractory precursor lymphocytic leukemia/lymphoma patients. Methods 6 patients with relapsed/ refractory precursor lymphocytic leukemia/lymphoma including 2 acute lymphocytic leukemia, 4 lymphob]ast lymphoma and 1 hybrid acute leukemia were treated by combination of CAG regimen with L-asparaginase （L-Asp） and prednisone （PDN）. Results All patients responded to the regimen, in which 6/7 （85.7 %） patients achieved complete remission and 1/7 （14.3 %） patient achieved partial remission after one course. Light adverse events coursed by the regimen could be tolerated. Conclusion The regimen consisting of CAG, PDN and L-Asp is worth exploring for relapsed/refractory precursor lymphocytic leukemia/ lymphoma.